Leflunomide ratiopharm 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0026 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/05/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IAIN/0025/G 
This was an application for a group of variations. 
04/08/2021 
n/a 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0024 
Minor change in labelling or package leaflet not 
23/07/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/08/2020 
28/07/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IAIN/0022 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/12/2017 
26/11/2018 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0020 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
15/12/2015 
22/09/2016 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0019/G 
This was an application for a group of variations. 
13/11/2015 
22/09/2016 
SmPC 
B.II.z - Quality change - Finished product - Other 
variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0018 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
24/09/2015 
22/09/2016 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
R/0015 
Renewal of the marketing authorisation. 
23/04/2015 
19/06/2015 
SmPC and PL 
IB/0017/G 
This was an application for a group of variations. 
23/04/2015 
13/05/2015 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 4/8 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0014 
B.III.1.a.2 - Submission of a new/updated or 
20/10/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0013 
Update of sections 4.4 and 4.8 of the SmPC following 
14/08/2014 
06/02/2015 
SmPC and PL 
the same changes for the reference product Arava. 
Sections 2 and 4 of the Package Leaflet have been 
updated accordingly. Additionally, some minor 
linguistic corrections have been performed in the 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
following languages: DA, DE, ES, FR, HR, IS, LT, NL, 
NO, PL, RO and SK to align the texts to the 
originator’s. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
10/04/2014 
n/a 
PRAC Recommendation - maintenance 
201309 
leflunomide 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/02/2014 
06/02/2015 
SmPC and PL 
Introduction of an additional statement on the reporting of 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
ADRs in the Product Information. Furthermore, the Croatian 
annexes have been included together with the Croatian 
affiliate in the list of local representatives. 
Additionally minor editorial changes in local representatives 
of Hungary, Croatia, Iceland and United Kingdom have 
been made. 
IAIN/0010 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/06/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/02/2013 
22/01/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/06/2012 
20/09/2012 
SmPC, Annex 
Implementation of changes approved in reference product 
generic/hybrid/biosimilar products following 
II, Labelling 
– update of section 4.4 to add a warning for peripheral 
assessment of the same change for the reference 
and PL 
neuropathy and the frequency of this event has been 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
changed to ‘common’ in section 4.8 as requested by CHMP. 
The PIL has been updated accordingly. Further updates 
concern the implementation of the latest QRD template. 
IA/0007 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
04/04/2012 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IB/0006 
Update of section 4.4 of the SmPC regarding the risk 
09/01/2012 
20/09/2012 
SmPC 
Update of section 4.4 of the SmPC regarding the risk of 
of leflunomide use in combination with biologicals 
following the CHMP assessment of the COLEBI study 
(FU2 038.1) as implemented in the originator 
product Arava II-49. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
leflunomide use in combination with biologicals following 
the CHMP assessment of the COLEBI study (FU2 038.1) as 
implemented in the originator product Arava II-49. 
IA/0005 
B.II.b.1.a - Replacement or addition of a 
26/10/2011 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/09/2011 
n/a 
SmPC and PL 
Update of sections 4.2 and 5.1 of the SmPC to reflect the 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
outcome of the clinical study R01143 (LEADER) regarding 
the use of a loading dose, as requested by CHMP. The MAH 
also took the opportunity to make minor linguistic 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data are submitted by the MAH 
corrections to align with the reference product and made 
changes to the contact details of the local representatives 
in the package leaflets. 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/08/2011 
n/a 
SmPC and PL 
Implementation of changes approved in reference product - 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
update of section 4.4 to amend the warning for interstitial 
lung disease (ILD) as requested by CHMP. The PIL was 
revised accordingly. In addition the description of the risk 
of teratogenicity in the PIL was strengthened. Further 
updates concern the implementation of the latest QRD 
template. In addition, the MAH made linguistic corrections 
in the bg, cs, de, el, fi, fr, hu, it, lv, mt, nl, ro, sl and sv 
language PI. 
II/0002 
Introduction of a new Pharmacovigilance system 
23/06/2011 
23/06/2011 
Following the acquisition of ratiopharm GmbH by the TEVA 
which has not been assessed by the relevant national 
competent authority/EMEA for another product of the 
same MAH. 
C.I.8.a - Introduction of a new Pharmacovigilance 
system - which has not been assessed by the 
relevant NCA/EMA for another product of the same 
MAH 
Group, the MAH has submitted this Type II variation to 
introduce a new Pharmacovigilance System (TEVA DDPS 
Version 10), including a new Qualified person for 
Pharmacovigilance, which has not been assessed yet by 
EMA for another product of the same MAH. 
IB/0001 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
08/03/2011 
n/a 
SmPC, Annex 
storage conditions of the finished product - Other 
II and Labelling 
variation 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
